INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 46m ago
HOUSE PTR6m ago
SEC 13F6m ago
ROBINHOOD CHAIN5m ago
Public company

WGSGeneDx Holdings Corp.

CIK 0001818331

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 34
Max Insider Score28
Connections6with evidence

WGS · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
22
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$144K
1,470 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 8000 · Services-Health Services · Nov 4, 2026
  • ← Insider ofevidence
    Gardner Mark APresident · Jul 1, 2026
  • ← Insider ofevidence
    Fuchs ThomasDirector · Jun 23, 2026
  • ← Insider ofevidence
    Dechairo BryanChief Operating Officer · Feb 3, 2026
22
SK
Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL
$14K
148 sh
Sep 16, 2026
Sep 18, 2026
traded Sep 16, 2026
+2d
SEC FORM 4

Evidence

22
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$107K
1,079 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

14
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
7,197 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

6
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
7,197 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

9
FT
Fuchs ThomasDirector
WGSGeneDx Holdings Corp.
Option exercise
M—
1,146 sh
Sep 17, 2026Sep 18, 2026
traded Sep 17, 2026
+1dSEC FORM 4

Evidence

25
SK
Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$155K
1,648 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

22
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$52K
541 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

28
SK
Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$301K
3,039 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

25
SK
Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$148K
1,525 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

28
SK
Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$407K
4,141 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

22
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$55K
586 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

9
SK
Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
18.8K sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

17
SK
Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
18.8K sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

19
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$4,961
52 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

21
FT
Fuchs ThomasDirector
WGSGeneDx Holdings Corp.
Option exercise
M—
1,146 sh
Sep 17, 2026Sep 18, 2026
traded Sep 17, 2026
+1dSEC FORM 4

Evidence

6
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
2,462 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

28
SK
Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$311K
3,692 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

5
SK
Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
6,547 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

9
SK
Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
6,547 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

14
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
2,462 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

22
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$108K
1,285 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

9
GA
Gardner Mark APresident
WGSGeneDx Holdings Corp.
Grant or award
A—
35.4K sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

15
FT
Fuchs ThomasDirector
WGSGeneDx Holdings Corp.
Grant or award
A—
4,248 sh
Jun 18, 2026Jun 23, 2026
traded Jun 18, 2026
+5dSEC FORM 4

Evidence

17
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$53K
863 sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

17
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$128K
2,106 sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

14
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
7,197 sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

14
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$45K
760 sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

6
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
7,197 sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

14
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
2,462 sh
Jun 9, 2026Jun 11, 2026
traded Jun 9, 2026
+2dSEC FORM 4

Evidence

6
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
2,462 sh
Jun 9, 2026Jun 11, 2026
traded Jun 9, 2026
+2dSEC FORM 4

Evidence

17
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$68K
1,266 sh
Jun 9, 2026Jun 11, 2026
traded Jun 9, 2026
+2dSEC FORM 4

Evidence

14
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$26K
392 sh
Apr 29, 2026May 1, 2026
traded Apr 29, 2026
+2dSEC FORM 4

Evidence

2
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
754 sh
Apr 29, 2026May 1, 2026
traded Apr 29, 2026
+2dSEC FORM 4

Evidence

2
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
754 sh
Apr 29, 2026May 1, 2026
traded Apr 29, 2026
+2dSEC FORM 4

Evidence

14
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
16.3K sh
Mar 26, 2026Mar 30, 2026
traded Mar 26, 2026
+4dSEC FORM 4

Evidence

21
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$159K
2,520 sh
Mar 26, 2026Mar 30, 2026
traded Mar 26, 2026
+4dSEC FORM 4

Evidence

21
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$121K
1,857 sh
Mar 26, 2026Mar 30, 2026
traded Mar 26, 2026
+4dSEC FORM 4

Evidence

17
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$64K
995 sh
Mar 26, 2026Mar 30, 2026
traded Mar 26, 2026
+4dSEC FORM 4

Evidence

14
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
16.3K sh
Mar 26, 2026Mar 30, 2026
traded Mar 26, 2026
+4dSEC FORM 4

Evidence

17
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$60K
961 sh
Mar 26, 2026Mar 30, 2026
traded Mar 26, 2026
+4dSEC FORM 4

Evidence

21
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$152K
2,485 sh
Mar 26, 2026Mar 30, 2026
traded Mar 26, 2026
+4dSEC FORM 4

Evidence

10
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
2,462 sh
Mar 9, 2026Mar 11, 2026
traded Mar 9, 2026
+2dSEC FORM 4

Evidence

6
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Option exercise
M—
2,462 sh
Mar 9, 2026Mar 11, 2026
traded Mar 9, 2026
+2dSEC FORM 4

Evidence

21
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$111K
1,280 sh
Mar 9, 2026Mar 11, 2026
traded Mar 9, 2026
+2dSEC FORM 4

Evidence

9
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Grant or award
A$175K
1,986 sh
Mar 6, 2026Mar 9, 2026
traded Mar 6, 2026
+3dSEC FORM 4

Evidence

21
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$111K
1,424 sh
Mar 4, 2026Mar 5, 2026
traded Mar 4, 2026
+1dSEC FORM 4

Evidence

14
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Grant or award
A—
15.3K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

2
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Grant or award
A—
10.4K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

2
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Grant or award
A—
10.9K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

21
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$200K
2,543 sh
Mar 4, 2026Mar 5, 2026
traded Mar 4, 2026
+1dSEC FORM 4

Evidence

21
FK
Feeley KevinCHIEF FINANCIAL OFFICER
WGSGeneDx Holdings Corp.
Open-market sale
SELL$176K
2,220 sh
Mar 4, 2026Mar 5, 2026
traded Mar 4, 2026
+1dSEC FORM 4

Evidence

21
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale · 10b5-1 plan
SELL$138K
1,572 sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

18
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale · 10b5-1 plan
SELL$9,192
100 sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

17
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale · 10b5-1 plan
SELL$54K
623 sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

17
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale · 10b5-1 plan
SELL$88K
1,034 sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

17
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale · 10b5-1 plan
SELL$119K
1,425 sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

13
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale · 10b5-1 plan
SELL$65K
779 sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

18
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale · 10b5-1 plan
SELL$9,045
100 sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

18
DB
Dechairo BryanChief Operating Officer
WGSGeneDx Holdings Corp.
Open-market sale · 10b5-1 plan
SELL$29K
328 sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

← Insider ofevidence
Stueland Katherine
Director, CHIEF EXECUTIVE OFFICER · Dec 11, 2025
  • ← Insider ofevidence
    Feeley KevinCHIEF FINANCIAL OFFICER · Dec 11, 2025